Gili Hart

527 total citations
27 papers, 407 citations indexed

About

Gili Hart is a scholar working on Endocrinology, Diabetes and Metabolism, Immunology and Molecular Biology. According to data from OpenAlex, Gili Hart has authored 27 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Gili Hart's work include Growth Hormone and Insulin-like Growth Factors (9 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Gili Hart is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (9 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Gili Hart collaborates with scholars based in Israel, United States and United Kingdom. Gili Hart's co-authors include Idit Shachar, Liat Flaishon, Oren Hershkovitz, Ronit Koren, Ron G. Rosenfeld, Shirly Becker-Herman, A. H. Crisp, J. Hubert Lacey, Eyal Fima and Tamar Avin‐Wittenberg and has published in prestigious journals such as Blood, The Journal of Immunology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Gili Hart

26 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gili Hart Israel 13 153 130 99 80 50 27 407
Shobha Varma United States 7 180 1.2× 61 0.5× 85 0.9× 64 0.8× 21 0.4× 8 345
Sally A. Clayton United Kingdom 7 36 0.2× 123 0.9× 69 0.7× 47 0.6× 14 0.3× 9 260
Maria Kalina Poland 9 113 0.7× 174 1.3× 39 0.4× 90 1.1× 37 0.7× 26 370
Hatsumi Yamamoto Japan 12 44 0.3× 171 1.3× 160 1.6× 14 0.2× 70 1.4× 29 520
S Justice United Kingdom 9 215 1.4× 62 0.5× 44 0.4× 40 0.5× 11 0.2× 12 400
Vickie Hannig United States 12 70 0.5× 175 1.3× 13 0.1× 185 2.3× 83 1.7× 19 494
Sibel Oğuzkan Balcı Türkiye 13 23 0.2× 115 0.9× 59 0.6× 25 0.3× 17 0.3× 48 404
Ljubica Bogić United States 12 41 0.3× 149 1.1× 85 0.9× 53 0.7× 57 1.1× 17 436
Eef Hoeben Belgium 14 70 0.5× 138 1.1× 40 0.4× 65 0.8× 16 0.3× 22 394
S Gough United Kingdom 9 190 1.2× 132 1.0× 91 0.9× 198 2.5× 19 0.4× 16 512

Countries citing papers authored by Gili Hart

Since Specialization
Citations

This map shows the geographic impact of Gili Hart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gili Hart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gili Hart more than expected).

Fields of papers citing papers by Gili Hart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gili Hart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gili Hart. The network helps show where Gili Hart may publish in the future.

Co-authorship network of co-authors of Gili Hart

This figure shows the co-authorship network connecting the top 25 collaborators of Gili Hart. A scholar is included among the top collaborators of Gili Hart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gili Hart. Gili Hart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ozeri-Galai, E., Matthew R. Markovetz, Yifat S. Oren, et al.. (2023). Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients. Nucleic Acid Therapeutics. 33(5). 306–318. 11 indexed citations
3.
Bar-Ilan, Ahuva, Tami Livnat, Matthew Hoffmann, et al.. (2018). In vitro characterization of MOD‐5014, a novel long‐acting carboxy‐terminal peptide (CTP)‐modified activated FVII. Haemophilia. 24(3). 477–486. 18 indexed citations
4.
Loftus, Jane, Andrew Yaworsky, L Morrissey, et al.. (2017). Caregiver Burden In Daily Human Growth Hormone Injections For Children. Value in Health. 20(9). A758–A758. 2 indexed citations
5.
Zelinska, Nataliya, Violeta Iotova, Valentina Peterkova, et al.. (2017). Long-Acting C-Terminal Peptide–Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children. The Journal of Clinical Endocrinology & Metabolism. 102(5). 1578–1587. 48 indexed citations
6.
Fisher, Dennis M., et al.. (2017). Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children. Hormone Research in Paediatrics. 87(5). 324–332. 31 indexed citations
7.
Strasburger, Christian J., Peter Vaňuga, Juraj Payer, et al.. (2016). MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. European Journal of Endocrinology. 176(3). 283–294. 38 indexed citations
8.
Cohen, Sivan, Ehud Zigmond, Elias Shezen, et al.. (2015). CD151 Regulates T-Cell Migration in Health and Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 22(2). 257–267. 17 indexed citations
9.
Zadik, Zvi, Ron G. Rosenfeld, Nataliya Zelinska, et al.. (2014). Top Line Results of Once-Weekly, CTP-Modified Human GH (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency. 82. 4 indexed citations
10.
11.
12.
Gore, Yael, Frida Lantner, Gili Hart, & Idit Shachar. (2010). Mad3 Negatively Regulates B Cell Differentiation in the Spleen by Inducing Id2 Expression. Molecular Biology of the Cell. 21(11). 1864–1871. 12 indexed citations
13.
Maharshak, Nitsan, Gili Hart, Adi Sagiv, et al.. (2010). CCL2 (pM levels) as a therapeutic agent in inflammatory bowel disease models in mice. Inflammatory Bowel Diseases. 16(9). 1496–1504. 15 indexed citations
14.
Flaishon, Liat, Gili Hart, Christine Moussion, et al.. (2008). Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions. Blood. 112(13). 5016–5025. 35 indexed citations
15.
Hart, Gili, Liat Flaishon, & Idit Shachar. (2007). IL‐12 and IL‐18 down‐regulate B cell migration in an Ly49D‐dependent manner. European Journal of Immunology. 37(7). 1996–2007. 7 indexed citations
16.
Hart, Gili, Tamar Avin‐Wittenberg, & Idit Shachar. (2007). IL-15 regulates immature B-cell homing in an Ly49D-, IL-12–, and IL-18–dependent manner. Blood. 111(1). 50–59. 15 indexed citations
17.
Hart, Gili, Liat Flaishon, Shirly Becker-Herman, & Idit Shachar. (2005). Tight Regulation of IFN-γ Transcription and Secretion in Immature and Mature B cells by the Inhibitory MHC Class I Receptor, Ly49G2. The Journal of Immunology. 175(8). 5034–5042. 7 indexed citations
18.
Flaishon, Liat, Shirly Becker-Herman, Gili Hart, et al.. (2004). Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration. Blood. 104(4). 933–941. 36 indexed citations
19.
Hart, Gili, Liat Flaishon, Shirly Becker-Herman, & Idit Shachar. (2003). Ly49D Receptor Expressed on Immature B Cells Regulates Their IFN-γ Secretion, Actin Polymerization, and Homing. The Journal of Immunology. 171(9). 4630–4638. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shobha Varma Breakdown of academic impact, for papers by Sally A. Clayton Breakdown of academic impact, for papers by Maria Kalina Breakdown of academic impact, for papers by Hatsumi Yamamoto Breakdown of academic impact, for papers by S Justice Breakdown of academic impact, for papers by Vickie Hannig Breakdown of academic impact, for papers by Sibel Oğuzkan Balcı Breakdown of academic impact, for papers by Ljubica Bogić Breakdown of academic impact, for papers by Eef Hoeben Breakdown of academic impact, for papers by S Gough
Rankless by CCL
2026